research 5α-Reductase Inhibitors: Evaluation of Their Potential Confounding Effect on GC-C-IRMS Doping Analysis
5α-reductase inhibitors can interfere with doping tests by masking banned substances.
Search
for
Sort by
Research
30-60 / 1000+ results 
research The Clinical Applications of Five-Alpha Reductase Inhibitors
Five-alpha reductase inhibitors, like finasteride and dutasteride, can treat enlarged prostates, improve urination, reduce need for prostate surgery, and lower the risk of prostate cancer, but may increase the risk of higher grade prostate cancer. They can also treat male pattern baldness.
research Long-Term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial
Finasteride reduces the need for prostate surgery but may increase the risk of depression and persistent sexual side effects.
research Post-Finasteride Syndrome Update: Point/Counterpoint
Finasteride's link to health issues like male breast cancer, infertility, and prostate cancer needs more research through placebo-controlled trials to confirm.
research Drug-Induced Gynecomastia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
Certain drugs, especially antiandrogens and spironolactone, significantly increase the risk of gynecomastia.
research Side Effects of 5-Alpha Reductase Inhibitors: A Comprehensive Review
5-alpha reductase inhibitors slightly increase the risk of sexual and mood side effects, and breast growth in men.
research A Review of the FAERS Data on 5-Alpha Reductase Inhibitors: Implications for Postfinasteride Syndrome
The review suggests younger men taking 1 mg finasteride report more side effects, including sexual, skin, metabolic, and psychological issues.
research Long-Term Oral Administration of 5α-Reductase Inhibitor Attenuates Erectile Function by Inhibiting Autophagy and Promoting Apoptosis of Smooth Muscle Cells in Corpus Cavernosum of Aged Rats
Long-term use of a certain medication can worsen erectile function in aged rats by damaging penile muscle cells.
research Male Breast Cancer and 5α-Reductase Inhibitors Finasteride and Dutasteride
Using finasteride or dutasteride does not increase the risk of male breast cancer.
research Efficacy and Safety of 5 Alpha-Reductase Inhibitor Monotherapy in Patients with Benign Prostatic Hyperplasia: A Meta-Analysis
5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.
research Association Between 5-Alpha Reductase Inhibitor Use and the Risk of Depression: A Meta-Analysis
Using 5-alpha reductase inhibitors may increase the risk of mild depression.
research Effects of 5-Alpha Reductase Inhibitors
5-alpha reductase inhibitors can cause sexual, neurologic, endocrine, and cardiovascular side effects, but these are rare and usually stop after ending treatment.
research Sexual Dysfunction After 5-Alpha Reductase Inhibitor Use: Insights from the Reduce Study Group Database
Dutasteride use can lead to a stable decline in sexual function that is not affected by age or prostate size.
research Risk of Depression After 5 Alpha Reductase Inhibitor Medication: Meta-Analysis
Taking 5 alpha reductase inhibitor medication slightly increases the risk of depression, especially as you get older.
research Comparison of Clinical Efficacy of Finasteride and Dutasteride as 5-Alpha Reductase Inhibitors
Dutasteride is more effective than Finasteride in reducing prostate size and PSA levels, but both drugs have similar side effects.
research Chronic Exposure of 5-Alpha Reductase Inhibitor in Young Male Rats Induces Metabolic Disturbance and Depressive-Like Behaviors
Long-term use of a drug for hair loss and prostate issues can cause metabolic problems and depression-like behavior in young male rats.
research Chronic Exposure With 5-Alpha Reductase Inhibitor Ameliorates Anxiety and Depression-Like Behaviors by Reducing Systemic Oxidative Stress in D-Galactose-Induced Aging Male Rats
Finasteride may help reduce anxiety and depression in elderly but might cause depression in young men.
research Trends in 5-Alpha Reductase Inhibitor Use Before and After the Food and Drug Administration Safety Warning
Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.
research Relative Efficacy of Minoxidil and the 5-Alpha Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients
Dutasteride is the most effective hair loss treatment after 24 weeks, but finasteride leads to the most hair growth after 48 weeks.
research Design of Liposome Formulations for CRISPR/Cas9 Enzyme Immobilization: Evaluation of 5-Alpha-Reductase Enzyme Knockout for Androgenic Disorders
New liposome treatment successfully delivers CRISPR to deactivate a key enzyme in androgen-related disorders.
research Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
Different drugs for prostate-related urinary symptoms work but have various side effects, and treatment should be tailored to the individual.
research The Impact of Monotherapies for Male Androgenetic Alopecia: A Network Meta-Analysis Study
"Dutasteride 0.5 mg daily is the most effective treatment for male hair loss."
research Is COVID-19 a Risk Factor for Progression of Benign Prostatic Hyperplasia and Exacerbation of Its Related Symptoms?: A Systematic Review
COVID-19 might worsen symptoms and progression of benign prostatic hyperplasia, possibly due to inflammation and metabolic disturbances in the prostate gland. More research is needed to confirm this.
research Can Long-Term LUTS/BPH Pharmacological Treatment Alter the Outcomes of Surgical Intervention?
Long-term medication for enlarged prostate might not clearly affect the timing or outcomes of later surgery.
research Leptomeningeal Angiomatosis Accompanied by Hair Follicle Nevus
A baby had a rare condition with abnormal blood vessels in the brain and unusual skin and hair growth, possibly a new syndrome.
research Long-Term Safety and Efficacy of Mirabegron and Solifenacin in Combination Compared with Monotherapy in Patients with Overactive Bladder: SYNERGY II Study
Using mirabegron and solifenacin together is safe and more effective for treating overactive bladder than using either drug alone.
research Finasteride and Dutasteride for the Treatment of Male Androgenetic Alopecia: A Review of Efficacy and Reproductive Adverse Effects
Finasteride and Dutasteride can improve hair growth in male baldness but may cause temporary sexual dysfunction and possibly affect fertility.
research US Food and Drug Administration Warning Regarding Finasteride and Suicidal Ideation: What Should Urologists Know?
Urologists should screen for mental health issues before and during finasteride treatment.
research Benign Prostatic Hyperplasia And Male Lower Urinary Symptoms: A Guide For Family Physicians
Family doctors can manage older men with urinary symptoms using exams, tests, and medications.
research Serenoa Repens Induced Erectile Dysfunction: Underdiagnosis and Phytovigilance
Saw palmetto may cause erectile dysfunction and needs better safety monitoring.